LOPID Drug Patent Profile

When do Lopid patents expire, and what generic alternatives are available?

Lopid is a drug marketed by Pfizer Pharms and is included in one NDA.

The generic ingredient in LOPID is gemfibrozil. Thirty-two suppliers are listed for this compound. Additional details are available on the gemfibrozil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lopid

A generic version of LOPID was approved as gemfibrozil by CHARTWELL MOLECULES on September 27^th, 1993.

Summary for LOPID

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	134
Patent Applications:	4,693
Drug Prices:	Drug price information for LOPID
What excipients (inactive ingredients) are in LOPID?	LOPID excipients list
DailyMed Link:	LOPID at DailyMed

See drug prices for LOPID

See drug sales revenues for LOPID

Pharmacology for LOPID

Drug Class	Peroxisome Proliferator Receptor alpha Agonist
Mechanism of Action	Peroxisome Proliferator-activated Receptor alpha Agonists

US Patents and Regulatory Information for LOPID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer Pharms	LOPID	gemfibrozil	CAPSULE;ORAL	018422-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer Pharms	LOPID	gemfibrozil	CAPSULE;ORAL	018422-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer Pharms	LOPID	gemfibrozil	TABLET;ORAL	018422-003	Nov 20, 1986	AB	RX	Yes	Yes

Expired US Patents for LOPID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer Pharms	LOPID	gemfibrozil	CAPSULE;ORAL	018422-001	Approved Prior to Jan 1, 1982
Pfizer Pharms	LOPID	gemfibrozil	CAPSULE;ORAL	018422-002	Approved Prior to Jan 1, 1982

International Patents for LOPID

See the table below for patents covering LOPID around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	291228
France	2008997
Germany	1925423
South Africa	6905769
United Kingdom	1225575

Market Dynamics and Financial Trajectory for LOPID (Gemfibrozil)

Introduction to LOPID (Gemfibrozil)

LOPID, known generically as gemfibrozil, is a fibric acid derivative used primarily to lower triglycerides and cholesterol levels in the blood. It is commonly prescribed for conditions such as high cholesterol, hyperlipoproteinemia, and to reduce the risk of cardiovascular disease.

Market Size and Growth

The lipid-lowering drugs market, which includes LOPID, is projected to experience significant growth. The global lipid-lowering drugs market was valued at USD 33.12 billion in 2023 and is anticipated to reach USD 46.58 billion by 2033, growing at a CAGR of 3.47% from 2024 to 2033[1].

Segmentation and Distribution Channels

LOPID falls under the fibrates segment of lipid-lowering drugs. The market is segmented by drug type, indication, and distribution channel. Retail pharmacies dominated the market in 2023 due to their higher preference and easy access, although online pharmacies are expected to witness notable growth during the forecast period[1].

Pricing and Cost Factors

The cost of LOPID can vary significantly based on several factors, including the pharmacy, insurance coverage, and the quantity prescribed. For cash-paying customers, a supply of 60 tablets of LOPID 600 mg can cost around $93. However, generic versions of gemfibrozil are available at a lower cost, starting from $26.64 for 30 tablets[2][5].

Financial Assistance and Savings Programs

To make LOPID more affordable, several financial assistance programs are available. These include patient assistance programs (PAPs) sponsored by pharmaceutical companies, copay cards, and savings coupons. For example, the Drugs.com Discount Card can save up to 80% on the cost of prescription medicines, and programs like Rx Outreach Medications and the Patient Access Network Foundation offer cost-free or discounted medicines to eligible individuals[2][5].

Regional Market Dynamics

North America leads the lipid-lowering drugs market, including LOPID, due to the high prevalence of cardiovascular diseases and a sedentary lifestyle among the population. This region's favorable regulatory environment and strong intellectual property protection also contribute to its dominance in the market[1].

Competitive Landscape

The market for lipid-lowering drugs is competitive, with major players such as Pfizer Inc., Novartis AG, AstraZeneca, Merck & Co., Inc., and others. These companies invest heavily in research and development, which drives innovation and growth in the market[4].

Impact of Generic Availability

The availability of generic versions of gemfibrozil has significantly impacted the market dynamics. Generic drugs are considered as safe and effective as their brand-name counterparts but are generally cheaper. This has led to increased accessibility and affordability of lipid-lowering treatments, contributing to the overall growth of the market[5].

Chronic Disease Prevalence and Demand

The increasing prevalence of chronic diseases such as cardiovascular diseases, diabetes, and hypercholesterolemia drives the demand for lipid-lowering drugs like LOPID. These conditions are major causes of morbidity and mortality worldwide, making effective treatments essential for public health[1][3].

Innovations and Future Outlook

The future outlook for LOPID and similar drugs is influenced by advancements in drug delivery systems and therapeutic applications. For instance, lipid nanoparticles, which are used in various therapeutic applications, are experiencing significant growth due to their efficiency in drug delivery and targeting specific tissues. While LOPID itself is not a nanoparticle, the broader trend of innovative drug delivery systems indicates a promising future for lipid-lowering treatments[3].

Key Takeaways

• The global lipid-lowering drugs market, including LOPID, is expected to grow from USD 33.12 billion in 2023 to USD 46.58 billion by 2033.
• Retail pharmacies dominate the distribution channel, but online pharmacies are growing rapidly.
• Generic versions of gemfibrozil are available at lower costs, making the treatment more accessible.
• Financial assistance programs and savings coupons help reduce the cost burden on patients.
• North America leads the market due to high prevalence of cardiovascular diseases and favorable regulatory conditions.
• The increasing prevalence of chronic diseases drives the demand for lipid-lowering drugs.

Frequently Asked Questions (FAQs)

1. What is LOPID used for? LOPID (gemfibrozil) is used to lower triglycerides and cholesterol levels in the blood, primarily for conditions such as high cholesterol and hyperlipoproteinemia.

2. How much does LOPID cost? The cost of LOPID can vary, but for cash-paying customers, a supply of 60 tablets of LOPID 600 mg can cost around $93. Generic versions are available at a lower cost.

3. Are there any financial assistance programs for LOPID? Yes, there are patient assistance programs (PAPs), copay cards, and savings coupons available to help make LOPID more affordable.

4. Is LOPID covered by Medicare? It may be covered by Medicare, depending on the specific plan. Patients should check with their Medicare plan provider for details.

5. What is the impact of generic availability on the market? The availability of generic versions of gemfibrozil has made lipid-lowering treatments more accessible and affordable, contributing to the overall growth of the market.

Cited Sources:

1. Precedence Research - Lipid-lowering Drugs Market Size to Hit USD 46.58 Bn by 2033[1]
2. Drugs.com - Lopid Prices, Coupons, Copay Cards & Patient Assistance[2]
3. BioSpace - Lipid Nanoparticles Market Anticipated to Surge to US $2,387.98 Million by 2032[3]
4. Transparency Market Research - Lipid Disorder Treatment Market Analysis of Size & Trends 2031[4]
5. Medical News Today - Gemfibrozil and cost: Reducing long-term drug costs and more[5]